Trials / Completed
CompletedNCT02683239
Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
A Phase 3 Randomized, Double-blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Long-Term Safety and the Efficacy of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 5,331 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to describe the safety and tolerability of fasinumab, including adverse events of special interest (AESIs), in patients with pain due to radiographically-confirmed OA of the knee or hip.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fasinumab | Participants will receive sub-cutaneous (SC) injections of fasinumab |
| DRUG | Placebo | Participants will receive sub-cutaneous (SC) injections of matching placebo |
Timeline
- Start date
- 2016-02-17
- Primary completion
- 2020-12-01
- Completion
- 2021-06-15
- First posted
- 2016-02-17
- Last updated
- 2023-10-13
- Results posted
- 2023-10-13
Locations
149 sites across 21 countries: United States, Bulgaria, Chile, Colombia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Lithuania, Mexico, Peru, Poland, Romania, Russia, South Africa, Spain, Sweden, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT02683239. Inclusion in this directory is not an endorsement.